Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;7(12):6010-6019.
doi: 10.1002/cam4.1866. Epub 2018 Nov 8.

Local regression and control of T1-2 nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

Fen Xue  1   2 , Dan Ou  1   2 , Chaosu Hu  1   2 , Xiayun He  1   2
Affiliations

Local regression and control of T1-2 nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

Fen Xue et al. Cancer Med. 2018 Dec.

Abstract

Objective: To observe the local regression and control in T1-2 nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) and to analyze the related influencing factors.

Methods: Between January 2006 and June 2014, 247 consecutive T1-2 NPC patients treated with IMRT were retrospectively analyzed, with 126 (51.0%) N0-1 disease and 121 (49.0%) N2-3 disease. Among them, 72.9% received platinum-based chemotherapy. The prescribed dose to gross tumor volume was 66 Gy/30 fractions.

Results: By the end of IMRT, the chemoradiotherapy (CRT) group had higher local complete response (CR) rate compared with IMRT alone group (92.2% vs 74.6%, P < 0.001), but no significant difference was discovered in 5-year local control (LC) rate (95.1% vs 94.9%, P = 0.968). Of the rest 31 patients with residual nasopharyngeal lesions after IMRT, those received boost irradiation (67.7%) also showed no improvement in 5-year LC rate compared with the observational group (95.0% vs 100.0%, P = 0.307). With a median follow-up of 63 months, the estimated 5-year LC rate for the whole group was 95.1% (T1 vs T2: 95.9% vs 94.7%, P = 0.186). Prognostic factors for LC were found neither in univariate nor in multivariate analysis. Advanced N stage was found to be the only adverse prognostic factor for all the other survivals.

Conclusions: Excellent LC could be achieved in T1-2 NPC treated with IMRT. The addition of chemotherapy may offer short-term response benefit, but no significant LC benefit, so did boost irradiation. Attention should be attached to advanced N stage, the exploration of the recurrence-related factors, and the necessities of the additional treatment.

Keywords: T1-2 nasopharyngeal carcinoma; boost irradiation; chemotherapy; local control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The estimated 5‐year local control (A), overall survival (B), distance metastasis‐free survival (C), and progression‐free survival (D) rates between patients with T1 and T2 stage, respectively
Figure 2
Figure 2
The estimated 5‐year local control (A), overall survival (B), distance metastasis‐free survival (C), and progression‐free survival (D) rates between patients with N0‐1 and N2‐3 stage, respectively
See this image and copyright information in PMC

References

    1. Lee AW, Ma BB, Ng WT, Chan AT. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. J Clin Oncol. 2015;33:3356‐3364. - PubMed
    1. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC‐NPC meta‐analysis. Lancet Oncol. 2015;16:645‐655. - PubMed
    1. Al‐Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310‐1317. - PubMed
    1. Lu H, Yao M. The current status of intensity‐modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev. 2008;34:27‐36. - PubMed
    1. Kam MK, Chau RM, Suen J, Choi PH, Teo PM. Intensity‐modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 2003;56:145‐157. - PubMed

MeSH terms